Skip to main content
SpringerLink
Log in

Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children

  • Original Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The purpose of this investigation was to describe the evolution of serotypes and antibiotic susceptibility of Streptococcus pneumoniae strains isolated from both adults and children from the same population area with invasive pneumococcal disease (IPD) or acute otitis media (AOM), 5 years after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13). From 2009 to 2015, 839 strains of S. pneumoniae strains were collected (481 from adults and 358 from children). Serotyping by latex antisera and molecular methods was performed. Antimicrobial susceptibility was tested. Compared to 2009, the total number of strains isolated in 2015 decreased in children (263 vs. 53, respectively) and in adults (220 vs. 131, respectively). Serotype coverage of PCV13 for IPD decreased significantly in adults from 67.7% (149/220) to 25.2% (33/131) and in children from 75.1% (61/81) to 18.5% (5/27). Especially, serotypes 1, 7F and 19A decreased significantly in children, while serotypes 7F and 19A decreased significantly in adults. PCV13 serotypes involved in AOM decreased significantly over the 5-year period, from 85.7% (156/182) to 38.5% (10/26), and were more susceptible to penicillin, amoxicillin and cefotaxime, p < 0.05. Serotypes 8, 9N and 10A seemed to emerge in adults, whereas any serotype prevalence was observed in children. Between 2009 and 2015, the introduction of PCV13 has resulted in a significant decrease of the number of S. pneumoniae strains isolated from IPD in children as in adults. It highlights a strong herd effect of vaccination in adults.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Bogaert D, De Groot R, Hermans PWM (2004) Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4:144–154

    Article  CAS  PubMed  Google Scholar 

  2. De Lencastre H, Tomasz A (2002) From ecological reservoir to disease: the nasopharynx, day-care centres and drug-resistant clones of Streptococcus pneumoniae. J Antimicrob Chemother 50:75–81

    Article  PubMed  Google Scholar 

  3. AlonsoDeVelasco E, Verheul AF, Verhoef J, Snippe H (1995) Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines. Microbiol Rev 59:591–603

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Hausdorff WP, Feikin DR, Klugman KP (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5:83–93

    Article  PubMed  Google Scholar 

  5. Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac; ORP Networks (2015) Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine 33:359–66

    Article  CAS  PubMed  Google Scholar 

  6. Lepoutre A, Varon E, Georges S, Gutmann L, Lévy-Bruhl D (2008) Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001–2006. Euro Surveill 13(35): pii: 18962

  7. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance of the Emerging Infections Program Network (2003) Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med 348:1737–1746

    Article  PubMed  Google Scholar 

  8. Black S, Shinefield H, Baxter B, Austrian R, Elvin L, Hansen J, Lewis E, Fireman B (2006) Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 24:S79–S80

  9. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG; Active Bacterial Core Surveillance Team (2005) Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294:2043–2051

    Article  CAS  PubMed  Google Scholar 

  10. Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, Orenstein W, Stephens DS (2007) Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine 25:5390–5398

    Article  CAS  PubMed  Google Scholar 

  11. Dortet L, Ploy MC, Poyart C, Raymond J; ORP Ile de France Ouest (2009) Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn Microbiol Infect Dis 65:49–57

    Article  CAS  PubMed  Google Scholar 

  12. Grall N, Hurmic O, Al Nakib M, Longo M, Poyart C, Ploy MC, Varon E, Raymond J; ORP Ile de France Ouest (2011) Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine. Eur J Clin Microbiol Infect Dis 30:1511–1519

    Article  CAS  PubMed  Google Scholar 

  13. Hurmic O, Grall N, Al Nakib M, Poyart C, Grondin S, Ploy MC, Varon E, Raymond J; ORP Ile de France-Ouest Network (2014) Evidence of a clonal expansion of Streptococcus pneumoniae serotype 19A in adults as in children assessed by the DiversiLab® system. Eur J Clin Microbiol Infect Dis 33:2067–2073

  14. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet 368:1495–1502

    Article  CAS  PubMed  Google Scholar 

  15. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297:1784–1792

    Article  CAS  PubMed  Google Scholar 

  16. Hsu KK, Pelton SI (2003) Heptavalent pneumococcal conjugate vaccine: current and future impact. Expert Rev Vaccines 2:619–631

    Article  PubMed  Google Scholar 

  17. Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, Hennessy TW (2006) Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 193:1487–1494

    Article  PubMed  Google Scholar 

  18. Beall B, McEllistrem MC, Gertz RE Jr, Wedel S, Boxrud DJ, Gonzalez AL, Medina MJ, Pai R, Thompson TA, Harrison LH, McGee L, Whitney CG; Active Bacterial Core Surveillance Team (2006) Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 44:999–1017

    Article  PubMed  PubMed Central  Google Scholar 

  19. Farnham AC, Zimmerman CM, Papadouka V, Konty KJ, Zucker JR, Nattanmai GV, Jose S, Rosen JB (2015) Invasive pneumococcal disease following the introduction of 13-valent conjugate vaccine in children in New York City from 2007 to 2012. JAMA Pediatr 169(7):646–652

    Article  PubMed  Google Scholar 

  20. Regev-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tziba Y, Istomin V, Weinberger M, Miron D, Temper V, Rahav G, Dagan R; IAIPD group (2015) Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study. Vaccine 33(9):1135–1142

    Article  PubMed  Google Scholar 

  21. Rodrigo C, Bewick T, Sheppard C, Greenwood S, Mckeever TM, Trotter CL, Slack M, George R, Lim WS (2015) Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J 45(6):1632–1641

    Article  PubMed  Google Scholar 

  22. Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac; ORP Networks (2014) Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine 33(2):359–366

    Article  PubMed  Google Scholar 

  23. Janoir C, Lepoutre A, Gutmann L, Varon E (2016) Insight into resistance phenotypes ofemergent non 13-valent pneumococcal conjugate vaccine type pneumococci isolatedfrom invasive disease after 13-valent pneumococcal conjugate vaccine implementationin France. Open Forum Infect Dis 3(1):ofw020

  24. Pai R, Gertz RE, Beall B (2006) Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol 44:124–131

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceño R, Alemán J, Hudgens MG, Woods CW, Weber DJ (2014) Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J 33:637–642

    Article  PubMed  Google Scholar 

  26. Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML (2014) Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines 2:155–158

    Article  PubMed  PubMed Central  Google Scholar 

  27. García Gabarrot G, López Vega M, Pérez Giffoni G, Hernández S, Cardinal P, Félix V, Gabastou JM, Camou T; Uruguayan SIREVA II Group (2014) Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country. PLoS One 9:e112337

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R (2014) Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine 32:3452–3459

    Article  PubMed  Google Scholar 

  29. Kempf M, Varon E, Lepoutre A, Gravet A, Baraduc R, Brun M, Chardon H, Cremniter J, Croizé J, Dalmay F, Demachy MC, Fosse T, Grelaud C, Hadou T, Hamdad F, Koeck JL, Luce S, Mermond S, Patry I, Péchinot A, Raymond J, Ros A, Segonds C, Soullié B, Tandé D, Vergnaud M, Vernet-Garnier V, Wallet F, Gutmann L, Ploy MC, Lanotte P (2015) Decline in antibiotic resistance and changes in the serotype distribution of Streptococcus pneumoniae isolates from children with acute otitis media; a 2001–2011 survey by the French Pneumococcal Network. Clin Microbiol Infect 21:35–42

  30. Grau I, Ardanuy C, Cubero M, Benitez MA, Liñares J, Pallares R (2016) Declining mortality from adult pneumococcal infections linked to children’s vaccination. J Infect 72:439–449

    Article  PubMed  Google Scholar 

  31. van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M (2015) Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One 10(7):e0131494

    Article  PubMed  PubMed Central  Google Scholar 

  32. van der Linden M, Perniciaro S, Imöhl M (2015) Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis 15:207

    Article  PubMed  PubMed Central  Google Scholar 

  33. Tin Tin Htar M, Christopoulou D, Schmitt HJ (2015) Pneumococcal serotype evolution in Western Europe. BMC Infect Dis 15:419

    Article  PubMed  PubMed Central  Google Scholar 

  34. Horácio AN, Silva-Costa C, Lopes JP, Ramirez M, Melo-Cristino J; Portuguese Group for the Study of Streptococcal Infections (2016) Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012–2014) despite continued reductions in other 13-valent conjugate vaccine serotypes. Front Microbiol 7:1616

    Article  PubMed  PubMed Central  Google Scholar 

  35. Sá-Leão R, Pinto F, Aguiar S, Nunes S, Carriço JA, Frazão N, Gonçalves-Sousa N, Melo-Cristino J, de Lencastre H, Ramirez M (2011) Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype. J Clin Microbiol 49:1369–1375

    Article  PubMed  PubMed Central  Google Scholar 

  36. Varon E, Cohen R, Béchet S, Doit C, Levy C (2015) Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. Vaccine 33:6178–6185

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We sincerely thank all the members of the ORP Ile de France Ouest for the data collection: G. Arlet, L. Armand-Lefevre, E. Benabib, T. Billard-Pomares, G. Blanchard, E. Cambau, E. Carrer-Causseret, C. Doit, A. Claudinon, F. Doucet-Populaire, Agnès Ferroni, C. Freneaux, C. Guillet-Caruba, H. Lecuyer, V. Leflon-Guibout, M. Leneveu, Françoise Leturdu, A.C. Maherault, D. Moissenet, A. Mbadi, L. Raskine, F. Richardin, V. Sivadon-Tardy, C. Souffi, J. Tankovic, C. Verdet.

Author information

Authors and Affiliations

  1. University Paris 5, Hôpital Cochin, Bacteriologie, 27 rue du Faubourg Saint Jacques, 75674, Paris, France

    C. Hays, Q. Vermee, A. Agathine, A. Dupuis, C. Poyart & J. Raymond

  2. University Paris 5, Hôpital Georges Pompidou, CNR Pneumocoques, Paris 15, France

    E. Varon

  3. Observatoire Regional des Pneumocoques, Laboratoire de Bactériologie-Virologie-Hygiène, CHU Dupuytrein, 87042 Limoges, France

    M.-C. Ploy

Authors
  1. C. Hays
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Q. Vermee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Agathine
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Dupuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Varon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Poyart
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M.-C. Ploy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Raymond
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

and the ORP Ile de France Ouest

Corresponding author

Correspondence to J. Raymond.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

For this type of retrospective study, informed consent is not required.

Ethical approval

Isolates were stored and data were anonymised. Therefore, development of the typing scheme on stored and anonymised isolates in a retrospective study did not require ethical approval.

Funding

No grant was received for this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hays, C., Vermee, Q., Agathine, A. et al. Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children. Eur J Clin Microbiol Infect Dis 36, 831–838 (2017). https://doi.org/10.1007/s10096-016-2868-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-016-2868-5

Keywords

Search

Navigation